Overview

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Status:
Withdrawn

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

This is an open label pilot study evaluating the pharmacodynamics and safety of single agent olaparib administered at 300mg bid (twice a day) for 14 days orally in patients with human papillomavirus (HPV) -positive and human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC)

Phase:

Phase 1

Details

Lead Sponsor:

Yale University

Treatments:

Olaparib